ND
NDRA.US ENDRA Life Sciences Inc
- Market cap
- USD 6.61M
- P/E
- -
- P/B
- 1.05x
- ROE
- -36.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NDRA.US undervalued?
Graham numberThe Graham number of ENDRA Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ENDRA Life Sciences Inc fundamental analysis
No fundamental analysis for ENDRA Life Sciences Inc yet.
ENDRA Life Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vas…
Full company profileENDRA Life Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ENDRA Life Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 516K | 352K | 6.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 280K | 179K | 6.17K | -115K | -165K | -224K | -234K | -275K | -206K | - | - |
| Operating Income | -1.79M | -4.63M | -9.02M | -10.8M | -11.5M | -11.5M | -13.2M | -10.5M | -10.8M | -5.76M | -7.31M |
| EBITDA | -1.73M | -4.56M | -9.00M | -10.8M | -11.3M | -11.0M | -12.9M | -9.78M | -11.3M | -6.87M | -5.43M |
| Net Income | -2.78M | -5.38M | -9.80M | -13.3M | -11.7M | -11.2M | -13.2M | -10.1M | -11.5M | -7.03M | -2.30M |
| EPS | -14 | -27 | -43 | -35 | -12 | -5.49 | -6.83 | -5.89 | -10 | -8.93 | -0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 491K | 6.12M | 7.22M | 7.18M | 8.76M | 12.9M | 9.27M | 6.75M | 4.45M | 3.85M | 7.94M |
| Total Liabilities | 1.38M | 848K | 975K | 2.42M | 1.60M | 2.09M | 2.07M | 1.10M | 1.89M | 1.59M | 1.63M |
| Shareholders' Equity | -894K | 5.28M | 6.25M | 4.76M | 7.17M | 10.8M | 7.20M | 5.66M | 2.56M | 2.26M | 6.31M |
| Cash & Short-term Investments | 145K | 5.60M | 6.47M | 6.17M | 7.23M | 9.46M | 4.89M | 2.83M | 3.23M | 762K | 1.74M |
| Total Debt | 950K | - | 22.51 | 773K | 769K | 796K | 547K | 394K | 754K | 492K | 429K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.32M | -3.30M | -7.70M | -8.59M | -10.8M | -11.1M | -12.8M | -9.55M | -7.40M | -5.18M | -4.09M |
| Capital Expenditure | 7.86K | 7.86K | 100K | 43.6K | 51.3K | 45.0K | 203K | 33.9K | 16.0K | 17.3K | 37.3K |
| Free Cash Flow | -1.32M | -3.31M | -7.80M | -8.63M | -10.8M | -11.2M | -13.0M | -9.58M | -7.42M | -5.20M | -4.13M |
| Ratios | |||||||||||
| ROE | - | -101.9% | -156.8% | -279.5% | -163.6% | -104.1% | -182.9% | -177.8% | -449.5% | -310.9% | -36.5% |
| ROA | -565.5% | -87.8% | -135.6% | -185.4% | -133.8% | -87.2% | -142.1% | -148.9% | -258.5% | -182.4% | -29.0% |
| Net Profit Margin | -538.3% | -1,529.2% | -158,669.6% | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | 0.00x | 0.16x | 0.11x | 0.07x | 0.08x | 0.07x | 0.29x | 0.22x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ENDRA Life Sciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 5.23K | 0.00 | - |
| 2023 | USD 840.00 | 0.00 | - |
| 2022 | USD 7.79K | 0.00 | - |
| 2021 | USD 121K | 0.06 | - |
| 2020 | USD 396K | 0.41 | - |
| 2019 | USD 4.22M | 11 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:35 on Nov 7, 2024.
Who owns ENDRA Life Sciences Inc
- Insiders 18.42%
- Institutions 26.36%
- Public & others 55.22%
- Shares outstanding 1.50M
- Free float 1.25M
Top funds holding NDRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 6.55K | 0.44% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.98K | 0.20% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 1.60K | 0.11% | 0.00% | Sep 2026 |
Top institutions holding NDRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Altium Capital Management, LP | 59.3K | 3.95% | +14.20% | Jun 2026 |
| Citadel Advisors Llc | 29.9K | 2.00% | 0.00% | Jun 2026 |
| Citizens Financial Group Inc | 28.4K | 1.89% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 18.8K | 1.25% | 0.00% | Sep 2026 |
| Geode Capital Management, LLC | 14.9K | 0.99% | -29.26% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 10.1K | 0.67% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.34K | 0.49% | +160.62% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.55K | 0.24% | 0.00% | Jun 2026 |
| UBS Group AG | 68.00 | 0.00% | -55.26% | Jun 2026 |
| Tower Research Capital LLC | 58.00 | 0.00% | 0.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 19.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | -100.00% | Jun 2026 |
ENDRA Life Sciences Inc company profile
- Company name
- ENDRA Life Sciences Inc
- Ticker
- NDRA.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2017
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 9
- Fiscal year end
- December
- Address
- 3600 Green Court, Ann Arbor, MI, United States, 48105-1570
- Phone
- 734 335 0468
- Website
- endrainc.com
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
ENDRA Life Sciences Inc management
6- Mr. Alexander Y. TokmanCEO & Chairman · born 1962
- Mr. Richard JacrouxCFO & Secretary · born 1968
- Dr. Jonathan Behr Ph.D.Co-Founder
- Mr. Scott SoberHead of Operations
- Mr. Ziad Rouag J.D.Head of Regulatory & Clinical Affairs
- Mr. Idan SteinbergHead of Engineering